Statement of Organization, Functions, and Delegations of Authority, 89-92 [2021-28386]
Download as PDF
<![CDATA[
89
Federal Register / Vol. 87, No. 1 / Monday, January 3, 2022 / Notices
EXHIBIT 2—ESTIMATED ANNUALIZED COST BURDEN
Number of
respondents
Total
burden hours
Average
hourly
wage rate *
Total cost
burden
1,800
900
$44.31
$39,879
Total .................................................................................................................
* Based upon the mean of the average wages for Life Scientists, All Other (19–1099), National Compensation Survey: Occupational Employment Statistics, May 2020 National Occupational Employment and Wage Estimates United States, U.S. Department of Labor, Bureau of Labor
Statistics. https://www.bls.gov/oes/current/oes_nat.htm#19-0000.
Request for Comments
In accordance with the Paperwork
Reduction Act, 44 U.S.C. 3501–3520,
comments on AHRQ’s information
collection are requested with regard to
any of the following: (a) Whether the
proposed collection of information is
necessary for the proper performance of
AHRQ’s health care research and health
care information dissemination
functions, including whether the
information will have practical utility;
(b) the accuracy of AHRQ’s estimate of
burden (including hours and costs) of
the proposed collection(s) of
information; (c) ways to enhance the
quality, utility and clarity of the
information to be collected; and (d)
ways to minimize the burden of the
collection of information upon the
respondents, including the use of
automated collection techniques or
other forms of information technology.
Comments submitted in response to
this notice will be summarized and
included in the Agency’s subsequent
request for OMB approval of the
proposed information collection. All
comments will become a matter of
public record.
Dated: December 28, 2021.
Marquita Cullom,
Associate Director.
[FR Doc. 2021–28441 Filed 12–30–21; 8:45 am]
BILLING CODE 4160–90–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
Statement of Organization, Functions,
and Delegations of Authority
AGENCY:
Food and Drug Administration,
HHS.
khammond on DSKJM1Z7X2PROD with NOTICES
ACTION:
Notice.
The Food and Drug
Administration’s (FDA), Center for
Biologics Evaluation and Research
(CBER), Center for Drug Evaluation and
Research (CDER), Center for Devices and
Radiological Health (CDRH), and Center
for Tobacco Products (CTP) have
modified their organizational structures.
SUMMARY:
VerDate Sep<11>2014
17:14 Dec 30, 2021
Jkt 256001
These new organizational structures
were approved by the Deputy Secretary
of Health and Human Services and
effective on November 24, 2021.
FOR FURTHER INFORMATION CONTACT:
Yashika Rahaman, Director, Office of
Planning, Evaluation and Risk
Management, Office of Finance, Budget,
Acquisitions and Planning, FDA, 4041
Powder Mill Road, Beltsville, MD
20705–4304, 301–796–3843.
I. Introduction
Part D, Chapter D–B, (Food and Drug
Administration), the Statement of
Organization, Functions and
Delegations of Authority for the
Department of Health and Human
Services (35 FR 3685, February 25,
1970, 60 FR 56606, November 9, 1995,
64 FR 36361, July 6, 1999, 72 FR 50112,
August 30, 2007, 74 FR 41713, August
18, 2009, 76 FR 45270, July 28, 2011,
and 84 FR 22854, May 20, 2019) is
revised to reflect the Food and Drug
Administration’s reorganizations of
CBER, CDER’s Office of Medical Policy
(OMP), Office of Prescription Drug
Promotion (OPDP), CDRH’s Office of
Product Evaluation and Quality, and
CTP’s Office of Compliance and
Enforcement and Office of Science.
This reorganization will help to
enhance these organization’s ability to
advance FDA’s mission and streamline
operations and support functions.
The Center for Biologics Evaluation
and Research’s organizational changes
in the Office of the Center Director (OD),
the Office of Management, and the
Office of Communications, Outreach,
and Development refocus functions that
support CBER’s product offices to better
support the expected growth in those
offices. The OD’s functions are
streamlined into those that require
intensive engagement from the Center
Director and have no other natural
home. Several responsibilities are
realigned or consolidated to leverage
synergies with other functions.
Harnessing the power of real-world
evidence is a priority in the FDA
Priority Framework, the 21st Century
Cures Act, and the PDUFA commitment
letter. The changes proposed to CBER’s
Office of Biostatistics and Epidemiology
PO 00000
Frm 00024
Fmt 4703
Sfmt 4703
(OBE) position the center to advance
real-world evidence priorities for
biologics.
The 21st Century Cures Act
established the Regenerative Medicine
Advanced Therapy (RMAT) designation
program, in Office of Tissues and
Advanced Therapies (OTAT), and called
on FDA to work to advance standards
development for regenerative medicine
products in order to support the
development, evaluation, and review of
regenerative medicine products. The
RMAT program has generated
tremendous industry interest, and CBER
has granted 129 RMAT designations
since program inception in December
2016.
One of FDA’s key priorities is
leveraging innovation to advance public
health goals by continually improving
the product development process and
strengthening FDA’s gold standard.
CBER’s portfolio of products is currently
seeing an unprecedented level of
innovation and growth. These
innovations range from the development
of new pathogen inactivation
technology that has the potential to
drastically improve how FDA promotes
blood safety, the explosion in
submissions for gene therapies that have
the potential to transform patients’ lives,
innovations in approaches to managing
serious food allergies, and advances in
manufacturing technology for vaccines.
The changes proposed in two of CBER’s
product offices: OTAT and the Office of
Blood Research and Review (OBRR)
along with the crosscutting functions in
OBE and Office of Compliance and
Biologics Quality are intended to ensure
CBER’s regulatory structures and
processes are prepared to respond to
innovation and development in the
industry while upholding FDA’s
standards for safety and effectiveness for
biological products. Establishing the
Office of Regulatory Operations will
help CBER support continued efficiency
and effectiveness in CBER’s regulatory
processes and provide strategic
direction as the Center works to
modernize its supporting information
technology (IT) infrastructure.
The Center for Drug Evaluation and
Research’s OMP, Office of Prescription
E:\FR\FM\03JAN1.SGM
03JAN1
khammond on DSKJM1Z7X2PROD with NOTICES
90
Federal Register / Vol. 87, No. 1 / Monday, January 3, 2022 / Notices
Drug Promotion (OPDP) establishes the
Division of Promotion Policy, Research,
and Operations (DPPRO). This
reorganization is critical to the FDA’s
ability to foster efficient oversight and
development of national prescription
drug promotion policy to enhance the
dissemination and communication of
high-quality drug information to
healthcare professionals, patients, and
consumers. The reorganization will also
provide enhanced support, oversight,
and direction to the OPDP’s social
science research program. This program
is critical in helping shape the direction
of OPDP’s new and evolving policy
initiatives through research studies
designed to evaluate the impact of
health communication and prescription
drug promotion directed toward
healthcare professionals and consumers.
The reorganization will provide
additional support and increased focus
on the regulatory counsel functions
necessary to develop sound and legally
supportable policy documents and
surveillance activities, particularly
given First Amendment jurisprudence
developments over the last few years.
The reorganization will also provide
enhanced operational support to all
OPDP functions, including policy
development and clearance, the
multimillion-dollar research program,
advisory comments to industry,
compliance actions, and internal FDA
review of approved labeling other
activities.
The Center for Devices and
Radiological Health’s Office of Product
Evaluation and Quality’s (OPEQ) retitles
the Office of In Vitro Diagnostics and
Radiological Health (OIR) as the Office
of Health Technology VII (OHT VII) and
establish an Office of Health Technology
VIII (OHT VIII) allowing the two offices
to have greater focus on In Vitro
Diagnostics (OHT VII) and
Mammography and Radiological Health
(OHT VIII). The OHT VII structure will
mirror the former OIR with the
exception of abolishing two divisions
(Division of Radiological Health and
Division of Mammography Quality
Standards). OHT VII will be solely
focused on in vitro diagnostics with
responsibility for regulating laboratory
and in-home diagnostic tests. In vitro
diagnostic devices allow for tests to be
completed using blood or tissue from
the human body. The results of these
tests are used to identify diseases and
other conditions. The devices allow for
individuals to monitor their health, and
they help to treat, cure, and prevent
diseases. Personnel utilizing the
precision medicine approach utilize in
vitro diagnostic devices in order to help
VerDate Sep<11>2014
17:14 Dec 30, 2021
Jkt 256001
identify individuals who can improve
their health by undergoing specific
therapies or treatments. The
Mammography Quality Standards
program will move in tact with its entire
appropriated and User Fee budget to the
OHT VIII and will continue to serve as
the national focal point for the
implementation of the Mammography
Quality Standards Act.
The Center for Tobacco Products’
Office of Compliance and Enforcement
(OCE) establishes the Division of
External Programs and Resource
Management (DEPRM) and establishes
the Division of Product Compliance
(DPC). The CTP’s Office of Science (OS)
establishes the Division of Research and
Knowledge Integration (DRKI). These
reorganizations are critical to the FDA’s
ability to better utilize its resources in
an efficient and effective way to meet its
mission of promoting and protecting the
public health by ensuring industry
compliance with the requirements of the
law and respond to public health
emergencies. The reorganizations will
also result in increased support of
requirements of the Family Smoking
Prevention and Tobacco Control Act.
The Food and Drug Administration’s,
Center for Biologics Evaluation and
Research, Center for Drug Evaluation
and Research’s Office of Medical Policy,
the Center for Devices and Radiological
Health’s Office of Product Evaluation
and Quality, and the Center for Tobacco
Products’ Office of Compliance and
Enforcement and Office of Science has
been restructured as follows:
DCB. Organization. The Center for
Biologics Evaluation and Research is
headed by the Center Director, Center
for Biologics Evaluation and Research.
Center for Biologics Evaluation and
Research (DCB)
Office of the Center Director (DCBA)
Executive Operations Staff (DCBA1)
Regulations and Policy Staff (DCBA3)
Policy Staff (DCBA7)
Science Staff (DCBA8)
Office of Management (DCBB)
Division of Program Services (DCBBB)
Program Services Branch (DCBBB1)
Safety and Services Branch (DCBBB4)
Division of Scientific Advisors and
Consultants (DCBBC)
Division of Veterinary Services (DCBBD)
Division of Management Planning and
Analysis (DCBBE)
Capacity Planning and Management
Analysis Branch (DCBBE1)
Planning, Performance, and
Formulation Branch (DCBBE2)
Division of Acquisitions and Budget
Resources (DCBBF)
Acquisition Management Branch
(DCBBF1)
PO 00000
Frm 00025
Fmt 4703
Sfmt 4703
Budget Planning and Execution Branch
(DCBBF2)
Division of Human Capital (DCBBG)
Management Services Branch (DCBBG1)
Workforce Management Branch
(DCBBG2)
Office of Compliance and Biologics
Quality (DCBC)
Division of Case Management (DCBCA)
Blood and Tissue Compliance Branch
(DCBCA1)
Advertising and Promotional Labeling
Branch (DCBCA2)
Biological Drug and Device Compliance
Branch (DCBCA3)
Division of Inspections and Surveillance
(DCBCB)
Program Surveillance Branch (DCBCB1)
Bioresearch Monitoring Branch
(DCBCB2)
Division of Manufacturing and Product
Quality (DCBCC)
Product Release Branch (DCBCC1)
Manufacturing Review Branch 1
(DCBCC2)
Manufacturing Review Branch 2
(DCBCC3)
Applications Review Branch (DCBCC4)
Manufacturing Review Branch 3
(DCBCC5)
Division of Biological Standards and
Quality Control (DCBCD)
Laboratory of Analytical Chemistry and
Blood Related Products (DCBCD1)
Quality Assurance Branch (DCBCD2)
Laboratory of Microbiology, In-vivo
Testing and Standards (DCBCD3)
Laboratory of Analytical Chemistry
Branch (DCBCD4)
Laboratory of Biochemistry, Virology,
and Immunochemistry Branch
(DCBCD5)
Laboratory of Blood Related Products
Branch (DCBCD6)
Office of Biostatistics and
Pharmacovigilance (DCBD)
CBER Surveillance Program Staff
(DCBD1)
ABRA Staff (DCBD2)
Division of Biostatistics (DCBDA)
Vaccines Evaluation Branch (DCBDA1)
Therapeutics Evaluation Branch 1
(DCBDA2)
Device and Non-Clinical Evaluation
Branch (DCBDA3)
Therapeutics Evaluation Branch 2
(DCBDA4)
Division of Pharmacovigilance (DCBDB)
Pharmacovigilance Branch 1 (DCBDB1)
Pharmacovigilance Branch 2 (DCBDB2)
Pharmacovigilance Branch 3 (DCBDB3)
Office of Blood Research and Review
(DCBE)
Administrative Staff (DCBE1)
Division of Emerging and Transfusion
Transmitted Diseases (DCBEA)
Laboratory of Molecular Virology
(DCBEA1)
Laboratory of Parasitic and Emerging
Pathogens (DCBEA2)
E:\FR\FM\03JAN1.SGM
03JAN1
khammond on DSKJM1Z7X2PROD with NOTICES
Federal Register / Vol. 87, No. 1 / Monday, January 3, 2022 / Notices
Product Review Branch (DCBEA4)
Division of Blood Components and
Devices (DCBEB)
Devices Review Branch (DCBEB2)
Laboratory of Biochemistry and
Vascular Biology (DCBEB5)
Laboratory of Cellular Hematology and
Vascular Biology Branch (DCBEB6)
Division of Clinical and Regulatory
Review (DCBEC)
Clinical Review Branch (DCBEC1)
Blood and Plasma Review Branch
(DCBEC2)
Regulatory Project Management Branch
(DCBEC3)
Office of Vaccine Research and Review
(DCBF)
Program Operations Staff (DCBF1)
Division of Bacterial, Parasitic, and
Allergenic Products (DCBFA)
Laboratory of Immunobiochemistry
(DCBFA1)
Laboratory of Respiratory and Special
Pathogens (DCBFA2)
Laboratory of Bacterial Polysaccharides
(DCBFA3)
Laboratory of Mucosal Pathogens and
Cellular Immunology (DCBFA4)
Division of Viral Products (DCBFB)
Laboratory of Pediatric and Respiratory
Viral Diseases (DCBFB1)
Laboratory of Hepatitis Viruses
(DCBFB2)
Laboratory of Retroviruses (DCBFB3)
Laboratory of DNA Viruses (DCBFB4)
Laboratory of Vector Borne Diseases
(DCBFB5)
Laboratory of Method Development
(DCBFB6)
Laboratory of Immunoregulation
(DCBFB7)
Division of Vaccines and Related
Products Applications (DCBFC)
CMC Review Branch 1 (DCBFC1)
CMC Review Branch 2 (DCBFC2)
CMC Review Branch 3 (DCBFC3)
Clinical Review Branch 1 (DCBFC4)
Clinical Review Branch 2 (DCBFC5)
Review Management Support Branch
(DCBFC6)
Office of Tissues and Advanced
Therapies (DCBG)
Division of Cellular and Gene Therapies
(DCBGA)
Cellular Therapies Branch (DCBGA1)
Gene Therapies Branch 1 (DCBGA2)
Gene Transfer and Immunogenicity
Branch (DCBGA3)
Tumor Vaccine and Biotechnology
Branch (DCBGA4)
Cellular and Tissue Therapy Branch
(DCBGA5)
Gene Therapies Branch 2 (DCBGA6)
Tissue Engineering Branch (DCBGA7)
Division of Clinical Evaluation and
Pharmacological/Toxicology (DCBGB)
General Medicine Branch 1 (DCBGB1)
Pharmacology/Toxicology Branch 1
(DCBGB2)
VerDate Sep<11>2014
17:14 Dec 30, 2021
Jkt 256001
Oncology Branch (DCBGB3)
General Medicine Branch 2 (DCBGB4)
Pharmacology/Toxicology Branch 2
(DCBGB5)
Malignant Hematology Branch
(DCBGB6)
General Medicine Branch 3 (DCBGB7)
Benign Hematology Branch (DCBGB8)
Division of Human Tissues (DCBGC)
Division of Plasma Protein Therapeutics
(DCBGD)
Hemostasis Branch (DCBGD1)
Plasma Derivatives Branch (DCBGD2)
Division of Regulatory Project
Management (DCBGE)
Regulatory Project Management Branch
1 (DCBGE1)
Regulatory Project Management Branch
2 (DCBGE2)
Regulatory Project Management Branch
3 (DCBGE3)
Regulatory Project Management Branch
4 (DCBGE4)
Office of Communication, Outreach, and
Development (DCBH)
Division of Disclosure and Oversight
Management (DCBHA)
Congressional and Oversight Branch
(DCBHA1)
Access Litigation and Freedom of
Information Branch (DCBHA2)
Electronic Disclosure Branch (DCBHA3)
Division of Manufacturers Assistance
and Training (DCBHB)
Career Development and Directed
Training Branch (DCBHB1)
Manufacturers Assistance & Technical
Training Branch (DCBHB2)
Division of Communication and
Consumer Affairs (DCBHC)
Communication Technology Branch
(DCBHC1)
Consumer Affairs Branch (DCBHC2)
Office of Regulatory Operations (DCBI)
Division of Informatics and Information
Technology (DCBIA)
Data Standards Branch (DCBIA1)
Information Technology Branch
(DCBIA2)
Records Management Branch (DCBIA3)
Regulatory Information Branch
(DCBIA4)
Division of Regulatory Operations and
Programs (DCBIB)
Regulatory Affairs and Business
Operations Branch (DCBIB1)
Regulatory Programs Branch (DCBIB2)
DCDH. Organization. The Center for
Drug Evaluation and Research’s Office
of Medical Policy is headed by the
Director, Office of Medical Policy and
includes the following:
Office of Medical Policy (DCDH)
Office of Prescription Drug Promotion
(DCDHA)
Division of Advertising and Promotion
Review I (DCDHAA)
Division of Advertising and Promotion
Review II (DCDHAB)
PO 00000
Frm 00026
Fmt 4703
Sfmt 4703
91
Division of Promotion Policy, Research,
and Operations (DCDHAC)
Office of Medical Policy Initiatives
(DCDHB)
Division of Medical Policy Development
(DCDHBA)
Division of Medical Policy Programs
(DCDHBB)
Division of Clinical Trial Quality
(DCDHBC)
DCCF. Organization. The Center for
Devices and Radiological Health’s Office
of Product Evaluation and Quality is
headed by the Director, Office Product
Evaluation and Quality and includes the
follow:
Office of Product Evaluation and
Quality (DCCF)
Quality and Analytics Staff (DCCF1)
Clinical and Scientific Policy Staff
(DCCF2)
Strategic Initiatives Staff (DCCF3)
Regulation, Policy and Guidance Staff
(DCCF4)
Office of Regulatory Programs (DCCFA)
Division of Regulatory Programs I
(DCCFAA)
Division of Regulatory Programs II
(DCCFAB)
Division of Regulatory Programs III
(DCCFAC)
Division of Regulatory Programs IV
(DCCFAD)
Office of Clinical Evidence and Analysis
(DCCFB)
Division of Clinical Evidence and
Analysis I (DCCFBA)
Division of Clinical Evidence and
Analysis II (DCCFBB)
Office of Health Technology I (DCCFC)
Division of Health Technology I A
(DCCFCA)
Division of Health Technology I B
(DCCFCB)
Division of Health Technology I C
(DCCFCC)
Office of Health Technology II (DCCFD)
Division of Health Technology II A
(DCCFDA)
Division of Health Technology II B
(DCCFDB)
Division of Health Technology II C
(DCCFDC)
Office of Health Technology III (DCCFE)
Division of Health Technology III A
(DCCFEA)
Division of Health Technology III B
(DCCFEB)
Division of Health Technology III C
(DCCFEC)
Office of Health Technology IV (DCCFF)
Division of Health Technology IV A
(DCCFFA)
Division of Health Technology IV B
(DCCFFB)
Office of Health Technology V (DCCFG)
Division of Health Technology V A
(DCCFGA)
E:\FR\FM\03JAN1.SGM
03JAN1
92
Federal Register / Vol. 87, No. 1 / Monday, January 3, 2022 / Notices
Division of Health Technology V B
(DCCFGB)
Office of Health Technology VI (DCCFH)
Division of Health Technology VI A
(DCCFHA)
Division of Health Technology VI B
(DCCFHB)
Division of Health Technology VI C
(DCCFHC)
Office of Health Technology VII (DCCFI)
Division of Chemistry and Toxicology
(DCCFIA)
Division of Immunology and
Hematology (DCCFIB)
Division of Microbiology (DCCFIC)
Division of Program Management and
Operations (DCCFIE)
Division of Molecular Genetics and
Pathology (DCCFIG)
Office of Health Technology VIII
(DCCFJ)
Division of Health Technology VIII A
(DCCFJA)
Division of Health Technology VIII B
(DCCFJB)
Division of Health Technology VIII C
(DCCFJC)
khammond on DSKJM1Z7X2PROD with NOTICES
DCFF. Organization. The Center for
tobacco Product’s Office of Compliance
and Enforcement is headed by the
Director, Office of Compliance and
Enforcement and includes the
following:
Division of Enforcement and
Manufacturing (DCFFA)
Division of Promotion, Advertising, and
Labeling (DCFFB)
Division of State Programs (DCFFC)
Division of Business Operations
(DCFFD)
Division of External Programs and
Resource Management (DCFFE)
Division of Product Compliance
(DCFFF)
DCFD. Organization. The Center for
tobacco Product’s Office of Science is
headed by the Director, Office of
Science and includes the following:
Division of Regulatory Project
Management (DCFDA)
Division of Regulatory Science
Informatics (DCFDB)
Division of Product Science (DCFDC)
Division of Individual Health Science
(DCFDD)
Division of Population Health Science
(DCFDE)
Division of Non-Clinical Sciences
(DCFDF)
Division of Research and Knowledge
Integration (DCFDG)
II. Delegations of Authority
Pending further delegation, directives,
or orders by the Commissioner of Food
and Drugs, all delegations and
redelegations of authority made to
officials and employees of affected
VerDate Sep<11>2014
17:14 Dec 30, 2021
Jkt 256001
organizational components will
continue in them or their successors
pending further redelegations, provided
they are consistent with this
reorganization.
III. Electronic Access
This reorganization is reflected in
FDA’s Staff Manual Guide (SMG).
Persons interested in seeing the
complete Staff Manual Guide can find it
on FDA’s website at: https://
www.fda.gov/AboutFDA/
ReportsManualsForms/
StaffManualGuides/default.htm.
Authority: 44 U.S.C. 3101.
Dated: October 22, 2021.
Andrea Palm,
Deputy Secretary of Health and Human
Services.
[FR Doc. 2021–28386 Filed 12–30–21; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2021–N–1243]
Prospective Grant of an Exclusive
Patent License: A Diagnostic Tool
Based Upon Magnetic Resonance
Spectroscopy Pre-Processing and
Renormalization
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is contemplating
the grant of an Exclusive Patent License
to practice the invention embodied in
the U.S. Patent listed in the
SUPPLEMENTARY INFORMATION section of
this notice to Voxel Systems, LLC
located in Houston, Texas.
SUMMARY:
Only written comments and/or
applications for a license that are
received by FDA’s Technology Transfer
Office on or before January 18, 2022,
will be considered.
DATES:
Inquiries and comments
relating to the contemplated Exclusive
Patent License should be directed to:
Ken Millburne, Food and Drug
Administration Technology Transfer
Office, Bldg. 1, Rm. 4213, Silver Spring,
MD 20993, 240–478–1662; email:
Kenneth.Millburne@fda.hhs.gov.
ADDRESSES:
SUPPLEMENTARY INFORMATION:
PO 00000
Frm 00027
Fmt 4703
Sfmt 4703
Intellectual Property
FDA Reference No.: E–2009–011/US–04:
‘‘System for Magnetic Resonance
Spectroscopy of Brain Tissue for
Pattern-Based Diagnostics’’
I. U.S. Non-Provisional Application
13/509,539, filed November 12, 2010
(FDA Reference No.: E–2009–011/US–
04).
II. U.S. Patent granted November 4,
2014: U.S. Patent 8,880,354 B2 (FDA
Reference No. E–2009–011/US–04).
The patent rights in this invention
have been assigned to the Government
of the United States of America.
The prospective exclusive license
territory may be worldwide and in fields
of use that may be limited to: (1) Any
and all in vivo use, application, or
developmental activity related to the
software, processing algorithm, and
Licensed Processes and Products; (2) all
human and animal diagnostics, in preclinical, or clinical utilizations for any
and all maladies; (3) all human research
applications for expanded magnetic
resonance imaging (MRI) utilization,
application development, drug
development tools, molecular
compound characterization, algorithms,
and biomarker identification and
development; and (4) all animal or other
research applications and translational
studies for ultra high-field MRI
investigations, drug development,
metabolite, and biomarker
identification.
This notice is made in accordance
with 35 U.S.C. 209 and 37 CFR part 404.
The prospective exclusive license will
be royalty bearing. The prospective
exclusive license may be granted unless,
within 15 days from the date of this
published notice, FDA receives written
evidence and argument that establishes
that the grant of the license would not
be consistent with the requirements of
35 U.S.C. 209 and 37 CFR part 404.
In response to this notice, the public
may file comments or objections.
Comments and objections, other than
those in the form of a license
application, will not be treated
confidentially, and may be made
publicly available.
License applications submitted in
response to this notice will be presumed
to contain business confidential
information and any release of
information in these license
applications will be made only as
required and upon a request under the
Freedom of Information Act, 5 U.S.C.
552.
E:\FR\FM\03JAN1.SGM
03JAN1
]]>Agencies
[Federal Register Volume 87, Number 1 (Monday, January 3, 2022)]
[Notices]
[Pages 89-92]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-28386]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
Statement of Organization, Functions, and Delegations of
Authority
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration's (FDA), Center for Biologics
Evaluation and Research (CBER), Center for Drug Evaluation and Research
(CDER), Center for Devices and Radiological Health (CDRH), and Center
for Tobacco Products (CTP) have modified their organizational
structures. These new organizational structures were approved by the
Deputy Secretary of Health and Human Services and effective on November
24, 2021.
FOR FURTHER INFORMATION CONTACT: Yashika Rahaman, Director, Office of
Planning, Evaluation and Risk Management, Office of Finance, Budget,
Acquisitions and Planning, FDA, 4041 Powder Mill Road, Beltsville, MD
20705-4304, 301-796-3843.
I. Introduction
Part D, Chapter D-B, (Food and Drug Administration), the Statement
of Organization, Functions and Delegations of Authority for the
Department of Health and Human Services (35 FR 3685, February 25, 1970,
60 FR 56606, November 9, 1995, 64 FR 36361, July 6, 1999, 72 FR 50112,
August 30, 2007, 74 FR 41713, August 18, 2009, 76 FR 45270, July 28,
2011, and 84 FR 22854, May 20, 2019) is revised to reflect the Food and
Drug Administration's reorganizations of CBER, CDER's Office of Medical
Policy (OMP), Office of Prescription Drug Promotion (OPDP), CDRH's
Office of Product Evaluation and Quality, and CTP's Office of
Compliance and Enforcement and Office of Science.
This reorganization will help to enhance these organization's
ability to advance FDA's mission and streamline operations and support
functions.
The Center for Biologics Evaluation and Research's organizational
changes in the Office of the Center Director (OD), the Office of
Management, and the Office of Communications, Outreach, and Development
refocus functions that support CBER's product offices to better support
the expected growth in those offices. The OD's functions are
streamlined into those that require intensive engagement from the
Center Director and have no other natural home. Several
responsibilities are realigned or consolidated to leverage synergies
with other functions. Harnessing the power of real-world evidence is a
priority in the FDA Priority Framework, the 21st Century Cures Act, and
the PDUFA commitment letter. The changes proposed to CBER's Office of
Biostatistics and Epidemiology (OBE) position the center to advance
real-world evidence priorities for biologics.
The 21st Century Cures Act established the Regenerative Medicine
Advanced Therapy (RMAT) designation program, in Office of Tissues and
Advanced Therapies (OTAT), and called on FDA to work to advance
standards development for regenerative medicine products in order to
support the development, evaluation, and review of regenerative
medicine products. The RMAT program has generated tremendous industry
interest, and CBER has granted 129 RMAT designations since program
inception in December 2016.
One of FDA's key priorities is leveraging innovation to advance
public health goals by continually improving the product development
process and strengthening FDA's gold standard. CBER's portfolio of
products is currently seeing an unprecedented level of innovation and
growth. These innovations range from the development of new pathogen
inactivation technology that has the potential to drastically improve
how FDA promotes blood safety, the explosion in submissions for gene
therapies that have the potential to transform patients' lives,
innovations in approaches to managing serious food allergies, and
advances in manufacturing technology for vaccines. The changes proposed
in two of CBER's product offices: OTAT and the Office of Blood Research
and Review (OBRR) along with the crosscutting functions in OBE and
Office of Compliance and Biologics Quality are intended to ensure
CBER's regulatory structures and processes are prepared to respond to
innovation and development in the industry while upholding FDA's
standards for safety and effectiveness for biological products.
Establishing the Office of Regulatory Operations will help CBER support
continued efficiency and effectiveness in CBER's regulatory processes
and provide strategic direction as the Center works to modernize its
supporting information technology (IT) infrastructure.
The Center for Drug Evaluation and Research's OMP, Office of
Prescription
[[Page 90]]
Drug Promotion (OPDP) establishes the Division of Promotion Policy,
Research, and Operations (DPPRO). This reorganization is critical to
the FDA's ability to foster efficient oversight and development of
national prescription drug promotion policy to enhance the
dissemination and communication of high-quality drug information to
healthcare professionals, patients, and consumers. The reorganization
will also provide enhanced support, oversight, and direction to the
OPDP's social science research program. This program is critical in
helping shape the direction of OPDP's new and evolving policy
initiatives through research studies designed to evaluate the impact of
health communication and prescription drug promotion directed toward
healthcare professionals and consumers. The reorganization will provide
additional support and increased focus on the regulatory counsel
functions necessary to develop sound and legally supportable policy
documents and surveillance activities, particularly given First
Amendment jurisprudence developments over the last few years. The
reorganization will also provide enhanced operational support to all
OPDP functions, including policy development and clearance, the
multimillion-dollar research program, advisory comments to industry,
compliance actions, and internal FDA review of approved labeling other
activities.
The Center for Devices and Radiological Health's Office of Product
Evaluation and Quality's (OPEQ) retitles the Office of In Vitro
Diagnostics and Radiological Health (OIR) as the Office of Health
Technology VII (OHT VII) and establish an Office of Health Technology
VIII (OHT VIII) allowing the two offices to have greater focus on In
Vitro Diagnostics (OHT VII) and Mammography and Radiological Health
(OHT VIII). The OHT VII structure will mirror the former OIR with the
exception of abolishing two divisions (Division of Radiological Health
and Division of Mammography Quality Standards). OHT VII will be solely
focused on in vitro diagnostics with responsibility for regulating
laboratory and in-home diagnostic tests. In vitro diagnostic devices
allow for tests to be completed using blood or tissue from the human
body. The results of these tests are used to identify diseases and
other conditions. The devices allow for individuals to monitor their
health, and they help to treat, cure, and prevent diseases. Personnel
utilizing the precision medicine approach utilize in vitro diagnostic
devices in order to help identify individuals who can improve their
health by undergoing specific therapies or treatments. The Mammography
Quality Standards program will move in tact with its entire
appropriated and User Fee budget to the OHT VIII and will continue to
serve as the national focal point for the implementation of the
Mammography Quality Standards Act.
The Center for Tobacco Products' Office of Compliance and
Enforcement (OCE) establishes the Division of External Programs and
Resource Management (DEPRM) and establishes the Division of Product
Compliance (DPC). The CTP's Office of Science (OS) establishes the
Division of Research and Knowledge Integration (DRKI). These
reorganizations are critical to the FDA's ability to better utilize its
resources in an efficient and effective way to meet its mission of
promoting and protecting the public health by ensuring industry
compliance with the requirements of the law and respond to public
health emergencies. The reorganizations will also result in increased
support of requirements of the Family Smoking Prevention and Tobacco
Control Act.
The Food and Drug Administration's, Center for Biologics Evaluation
and Research, Center for Drug Evaluation and Research's Office of
Medical Policy, the Center for Devices and Radiological Health's Office
of Product Evaluation and Quality, and the Center for Tobacco Products'
Office of Compliance and Enforcement and Office of Science has been
restructured as follows:
DCB. Organization. The Center for Biologics Evaluation and Research
is headed by the Center Director, Center for Biologics Evaluation and
Research.
Center for Biologics Evaluation and Research (DCB)
Office of the Center Director (DCBA)
Executive Operations Staff (DCBA1)
Regulations and Policy Staff (DCBA3)
Policy Staff (DCBA7)
Science Staff (DCBA8)
Office of Management (DCBB)
Division of Program Services (DCBBB)
Program Services Branch (DCBBB1)
Safety and Services Branch (DCBBB4)
Division of Scientific Advisors and Consultants (DCBBC)
Division of Veterinary Services (DCBBD)
Division of Management Planning and Analysis (DCBBE)
Capacity Planning and Management Analysis Branch (DCBBE1)
Planning, Performance, and Formulation Branch (DCBBE2)
Division of Acquisitions and Budget Resources (DCBBF)
Acquisition Management Branch (DCBBF1)
Budget Planning and Execution Branch (DCBBF2)
Division of Human Capital (DCBBG)
Management Services Branch (DCBBG1)
Workforce Management Branch (DCBBG2)
Office of Compliance and Biologics Quality (DCBC)
Division of Case Management (DCBCA)
Blood and Tissue Compliance Branch (DCBCA1)
Advertising and Promotional Labeling Branch (DCBCA2)
Biological Drug and Device Compliance Branch (DCBCA3)
Division of Inspections and Surveillance (DCBCB)
Program Surveillance Branch (DCBCB1)
Bioresearch Monitoring Branch (DCBCB2)
Division of Manufacturing and Product Quality (DCBCC)
Product Release Branch (DCBCC1)
Manufacturing Review Branch 1 (DCBCC2)
Manufacturing Review Branch 2 (DCBCC3)
Applications Review Branch (DCBCC4)
Manufacturing Review Branch 3 (DCBCC5)
Division of Biological Standards and Quality Control (DCBCD)
Laboratory of Analytical Chemistry and Blood Related Products (DCBCD1)
Quality Assurance Branch (DCBCD2)
Laboratory of Microbiology, In-vivo Testing and Standards (DCBCD3)
Laboratory of Analytical Chemistry Branch (DCBCD4)
Laboratory of Biochemistry, Virology, and Immunochemistry Branch
(DCBCD5)
Laboratory of Blood Related Products Branch (DCBCD6)
Office of Biostatistics and Pharmacovigilance (DCBD)
CBER Surveillance Program Staff (DCBD1)
ABRA Staff (DCBD2)
Division of Biostatistics (DCBDA)
Vaccines Evaluation Branch (DCBDA1)
Therapeutics Evaluation Branch 1 (DCBDA2)
Device and Non-Clinical Evaluation Branch (DCBDA3)
Therapeutics Evaluation Branch 2 (DCBDA4)
Division of Pharmacovigilance (DCBDB)
Pharmacovigilance Branch 1 (DCBDB1)
Pharmacovigilance Branch 2 (DCBDB2)
Pharmacovigilance Branch 3 (DCBDB3)
Office of Blood Research and Review (DCBE)
Administrative Staff (DCBE1)
Division of Emerging and Transfusion Transmitted Diseases (DCBEA)
Laboratory of Molecular Virology (DCBEA1)
Laboratory of Parasitic and Emerging Pathogens (DCBEA2)
[[Page 91]]
Product Review Branch (DCBEA4)
Division of Blood Components and Devices (DCBEB)
Devices Review Branch (DCBEB2)
Laboratory of Biochemistry and Vascular Biology (DCBEB5)
Laboratory of Cellular Hematology and Vascular Biology Branch (DCBEB6)
Division of Clinical and Regulatory Review (DCBEC)
Clinical Review Branch (DCBEC1)
Blood and Plasma Review Branch (DCBEC2)
Regulatory Project Management Branch (DCBEC3)
Office of Vaccine Research and Review (DCBF)
Program Operations Staff (DCBF1)
Division of Bacterial, Parasitic, and Allergenic Products (DCBFA)
Laboratory of Immunobiochemistry (DCBFA1)
Laboratory of Respiratory and Special Pathogens (DCBFA2)
Laboratory of Bacterial Polysaccharides (DCBFA3)
Laboratory of Mucosal Pathogens and Cellular Immunology (DCBFA4)
Division of Viral Products (DCBFB)
Laboratory of Pediatric and Respiratory Viral Diseases (DCBFB1)
Laboratory of Hepatitis Viruses (DCBFB2)
Laboratory of Retroviruses (DCBFB3)
Laboratory of DNA Viruses (DCBFB4)
Laboratory of Vector Borne Diseases (DCBFB5)
Laboratory of Method Development (DCBFB6)
Laboratory of Immunoregulation (DCBFB7)
Division of Vaccines and Related Products Applications (DCBFC)
CMC Review Branch 1 (DCBFC1)
CMC Review Branch 2 (DCBFC2)
CMC Review Branch 3 (DCBFC3)
Clinical Review Branch 1 (DCBFC4)
Clinical Review Branch 2 (DCBFC5)
Review Management Support Branch (DCBFC6)
Office of Tissues and Advanced Therapies (DCBG)
Division of Cellular and Gene Therapies (DCBGA)
Cellular Therapies Branch (DCBGA1)
Gene Therapies Branch 1 (DCBGA2)
Gene Transfer and Immunogenicity Branch (DCBGA3)
Tumor Vaccine and Biotechnology Branch (DCBGA4)
Cellular and Tissue Therapy Branch (DCBGA5)
Gene Therapies Branch 2 (DCBGA6)
Tissue Engineering Branch (DCBGA7)
Division of Clinical Evaluation and Pharmacological/Toxicology (DCBGB)
General Medicine Branch 1 (DCBGB1)
Pharmacology/Toxicology Branch 1 (DCBGB2)
Oncology Branch (DCBGB3)
General Medicine Branch 2 (DCBGB4)
Pharmacology/Toxicology Branch 2 (DCBGB5)
Malignant Hematology Branch (DCBGB6)
General Medicine Branch 3 (DCBGB7)
Benign Hematology Branch (DCBGB8)
Division of Human Tissues (DCBGC)
Division of Plasma Protein Therapeutics (DCBGD)
Hemostasis Branch (DCBGD1)
Plasma Derivatives Branch (DCBGD2)
Division of Regulatory Project Management (DCBGE)
Regulatory Project Management Branch 1 (DCBGE1)
Regulatory Project Management Branch 2 (DCBGE2)
Regulatory Project Management Branch 3 (DCBGE3)
Regulatory Project Management Branch 4 (DCBGE4)
Office of Communication, Outreach, and Development (DCBH)
Division of Disclosure and Oversight Management (DCBHA)
Congressional and Oversight Branch (DCBHA1)
Access Litigation and Freedom of Information Branch (DCBHA2)
Electronic Disclosure Branch (DCBHA3)
Division of Manufacturers Assistance and Training (DCBHB)
Career Development and Directed Training Branch (DCBHB1)
Manufacturers Assistance & Technical Training Branch (DCBHB2)
Division of Communication and Consumer Affairs (DCBHC)
Communication Technology Branch (DCBHC1)
Consumer Affairs Branch (DCBHC2)
Office of Regulatory Operations (DCBI)
Division of Informatics and Information Technology (DCBIA)
Data Standards Branch (DCBIA1)
Information Technology Branch (DCBIA2)
Records Management Branch (DCBIA3)
Regulatory Information Branch (DCBIA4)
Division of Regulatory Operations and Programs (DCBIB)
Regulatory Affairs and Business Operations Branch (DCBIB1)
Regulatory Programs Branch (DCBIB2)
DCDH. Organization. The Center for Drug Evaluation and Research's
Office of Medical Policy is headed by the Director, Office of Medical
Policy and includes the following:
Office of Medical Policy (DCDH)
Office of Prescription Drug Promotion (DCDHA)
Division of Advertising and Promotion Review I (DCDHAA)
Division of Advertising and Promotion Review II (DCDHAB)
Division of Promotion Policy, Research, and Operations (DCDHAC)
Office of Medical Policy Initiatives (DCDHB)
Division of Medical Policy Development (DCDHBA)
Division of Medical Policy Programs (DCDHBB)
Division of Clinical Trial Quality (DCDHBC)
DCCF. Organization. The Center for Devices and Radiological
Health's Office of Product Evaluation and Quality is headed by the
Director, Office Product Evaluation and Quality and includes the
follow:
Office of Product Evaluation and Quality (DCCF)
Quality and Analytics Staff (DCCF1)
Clinical and Scientific Policy Staff (DCCF2)
Strategic Initiatives Staff (DCCF3)
Regulation, Policy and Guidance Staff (DCCF4)
Office of Regulatory Programs (DCCFA)
Division of Regulatory Programs I (DCCFAA)
Division of Regulatory Programs II (DCCFAB)
Division of Regulatory Programs III (DCCFAC)
Division of Regulatory Programs IV (DCCFAD)
Office of Clinical Evidence and Analysis (DCCFB)
Division of Clinical Evidence and Analysis I (DCCFBA)
Division of Clinical Evidence and Analysis II (DCCFBB)
Office of Health Technology I (DCCFC)
Division of Health Technology I A (DCCFCA)
Division of Health Technology I B (DCCFCB)
Division of Health Technology I C (DCCFCC)
Office of Health Technology II (DCCFD)
Division of Health Technology II A (DCCFDA)
Division of Health Technology II B (DCCFDB)
Division of Health Technology II C (DCCFDC)
Office of Health Technology III (DCCFE)
Division of Health Technology III A (DCCFEA)
Division of Health Technology III B (DCCFEB)
Division of Health Technology III C (DCCFEC)
Office of Health Technology IV (DCCFF)
Division of Health Technology IV A (DCCFFA)
Division of Health Technology IV B (DCCFFB)
Office of Health Technology V (DCCFG)
Division of Health Technology V A (DCCFGA)
[[Page 92]]
Division of Health Technology V B (DCCFGB)
Office of Health Technology VI (DCCFH)
Division of Health Technology VI A (DCCFHA)
Division of Health Technology VI B (DCCFHB)
Division of Health Technology VI C (DCCFHC)
Office of Health Technology VII (DCCFI)
Division of Chemistry and Toxicology (DCCFIA)
Division of Immunology and Hematology (DCCFIB)
Division of Microbiology (DCCFIC)
Division of Program Management and Operations (DCCFIE)
Division of Molecular Genetics and Pathology (DCCFIG)
Office of Health Technology VIII (DCCFJ)
Division of Health Technology VIII A (DCCFJA)
Division of Health Technology VIII B (DCCFJB)
Division of Health Technology VIII C (DCCFJC)
DCFF. Organization. The Center for tobacco Product's Office of
Compliance and Enforcement is headed by the Director, Office of
Compliance and Enforcement and includes the following:
Division of Enforcement and Manufacturing (DCFFA)
Division of Promotion, Advertising, and Labeling (DCFFB)
Division of State Programs (DCFFC)
Division of Business Operations (DCFFD)
Division of External Programs and Resource Management (DCFFE)
Division of Product Compliance (DCFFF)
DCFD. Organization. The Center for tobacco Product's Office of
Science is headed by the Director, Office of Science and includes the
following:
Division of Regulatory Project Management (DCFDA)
Division of Regulatory Science Informatics (DCFDB)
Division of Product Science (DCFDC)
Division of Individual Health Science (DCFDD)
Division of Population Health Science (DCFDE)
Division of Non-Clinical Sciences (DCFDF)
Division of Research and Knowledge Integration (DCFDG)
II. Delegations of Authority
Pending further delegation, directives, or orders by the
Commissioner of Food and Drugs, all delegations and redelegations of
authority made to officials and employees of affected organizational
components will continue in them or their successors pending further
redelegations, provided they are consistent with this reorganization.
III. Electronic Access
This reorganization is reflected in FDA's Staff Manual Guide (SMG).
Persons interested in seeing the complete Staff Manual Guide can find
it on FDA's website at: https://www.fda.gov/AboutFDA/ReportsManualsForms/StaffManualGuides/default.htm.
Authority: 44 U.S.C. 3101.
Dated: October 22, 2021.
Andrea Palm,
Deputy Secretary of Health and Human Services.
[FR Doc. 2021-28386 Filed 12-30-21; 8:45 am]
BILLING CODE 4164-01-P
